🟢 Summit Therapeutics is trading 5% up today amid gains in biotech ETF XBI

Summit Therapeutics is trading 5% higher at $15.54 on November 3, amid strength across biotech stocks.

• Biotech ETF XBI is up 2.13% during the regular session amid rotation into biotech stocks.
• The shares are recovering from their November 2 close of $14.80. No new Summit-specific headline was identified for November 3; the prior AstraZeneca investment announcement is not a fresh catalyst. The S&P 500 and Nasdaq are modestly higher, while the Dow is lower.